Eli Lilly to acquire Seattle-area vaccine maker for $1.5 billion - The Seattle Times
Earnings
Eli Lilly is acquiring three vaccine biotechs in a ~$20B buying spree, including a Seattle-area vaccine maker for $1.5B, as it builds an infectious disease portfolio beyond its GLP-1 franchise. The deals signal LLY is diversifying revenue streams, but the scale of simultaneous acquisitions raises integration risk and near-term cash deployment concerns.
0 reads·0 theses
Angle
↓ SHORT-5% target+3% stop2-3 weeks, into Goldman Healthcare Conference
Fade the LLY pop short-term — $20B+ in simultaneous acquisitions at peak GLP-1 valuation historically pressures acquirer multiples; look to short into the Goldman Healthcare Conference catalyst or wait for a re-entry on pullback to $1,040-$1,050.